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Abstract: Aneurysmal subarachnoid hemorrhage (aSAH) is a high mortality hemorrhagic stroke that
affects nearly 30,000 patients annually in the United States. Approximately 30% of aSAH patients
die during initial hospitalization and those who survive often carry poor prognosis with one in five
having permanent physical and/or cognitive disabilities. The poor outcome of aSAH can be the
result of the initial catastrophic event or due to the many acute or delayed neurological complications,
such as cerebral ischemia, hydrocephalus, and re-bleeding. Unfortunately, no effective biomarker
exists to predict or diagnose these complications at a clinically relevant time point when neurologic
injury can be effectively treated and managed. Recently, a number of studies have demonstrated that
microRNAs (miRNAs) in extracellular biofluids are highly associated with aSAH and complications.
Here we provide an overview of the current research on relevant human studies examining the
correlation between miRNAs and aSAH complications and discuss the potential application of using
miRNAs as biomarkers in aSAH management.
Keywords: aneurysmal subarachnoid hemorrhage; delayed cerebral vasospasm; delay cerebral
ischemia; biomarker; microRNA; biofluid
1. Introduction
Aneurysmal subarachnoid hemorrhage (aSAH) occurs when an intracranial arterial
aneurysm ruptures, resulting in the release of oxygenated blood into the subarachnoid
space where it mixes with cerebrospinal fluid (CSF) [1]. In some cases, this blood may also
penetrate into the brain parenchyma or into the ventricular system, causing additional
injury [1,2]. aSAH accounts for approximately 5% of all strokes and affects relatively
younger individuals, compared to other types of stroke, with about 56% of the patients
being less than 60 years of age [3]. aSAH typically presents with a thunderclap headache
that is frequently described as the “worst headache of my life” by awake patients. On
computed tomography (CT) examination, there is classic high-attenuating filling of the
normally dark subarachnoid space, including in the cisterns and brain sulci. The ruptured
aneurysm is sometimes seen on special CT angiography or, more commonly, during
diagnostic digital subtraction angiography (DSA) procedures.
aSAH results in significant morbidity and mortality, resulting in death before or
during initial hospitalization in nearly 30% of aSAH patients, and in those patients who do
survive, almost 25% are at high risk of suffering secondary neurologic injuries resulting in
chronic, lifelong neurologic and functional disabilities [4,5]. Aside from the severe clinical
impact of the initial aneurysmal rupture, the poor prognosis can be caused by several
neurological complications such as delayed brain injury (DBI) [6–8], hydrocephalus [9,10],
and re-bleeding.
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DBI is the most significant cause of long-term poor prognosis and disability. DBI is a
heterogeneous term for several complex clinical phenomena, including delayed cerebral
vasospasm (DCV) and delayed cerebral ischemia (DCI). DBI events occur predominantly
4 to 10 days after aneurysm rupture in 30–70% of aSAH patients. Unfortunately, the
pathophysiology of DBI is poorly understood and effective treatment paradigms have not
translated well from the bench to the bedside.
DCI is consistently associated with highly negative clinical outcomes and perma-
nent disability. DCI occurs when there is an acute deterioration in neurologic status that
cannot be explained by the initial aneurysm rupture or its direct consequences. Various
mechanisms such as blood-brain barrier (BBB) disruption, inflammatory responses, micro-
circulatory dysfunction, microthrombosis, cortical spreading depression, and compromised
cerebral blood flow autoregulation have all been proposed [11]. The diagnosis of DCI is
often based on exclusion of other diagnoses such as infection, hypotension, hydrocephalus,
etc. [12], and is especially difficult to diagnose in patients who remain comatose from the
initial aneurysm rupture or who require sedation [13]. Understanding the exact mech-
anisms that lead to DCI will aid the discovery of effective biomarkers, as well as the
development of future treatment strategies.
DCV is also a major cause of DBI [8,14,15] and occurs when intracranial vessels spasm,
resulting in decreased blood flow to brain tissues distal to the site of spasm. Historically,
DCV was thought to lead directly to DCI if brain tissue perfusion was not rapidly restored.
DCV and DCI may be seen together in the same patients or separately without evidence
of the other [16–18]. In addition, a systematic review and meta-analysis of 14 studies
prior to 2009 showed that pharmaceutical treatments focused on reducing DCV did not
significantly improve clinical outcome [18]. However, this discordance could be a result of
study variations in pharmacological compounds, methodology, sample size, and clinical
outcome measures. On the other hand, a more recent meta-data analysis of 17 studies on
2870 aSAH patients reveals that evidence of cerebral vasospasm using transcranial doppler
is predictive of DCI with a high degree of sensitivity (90%) [19]. This suggests that DCV
prediction may be an important proxy for DCI, perhaps especially prior to its onset and
in high-grade aSAH patients in which the neurologic examination is obscured by acute
injury and/or sedation and the prevention of further secondary brain injury is critical for
survival.
Early diagnosis and treatment appear to be key to the clinical management of DBI,
however, due to the multifactorial nature of DBI, there is no reliable scoring system or
biomarker to predict DBI occurrence. Currently, diagnosis of these complications relies on
imaging and a “wait and see” approach, which often miss identifying the optimal treatment
times.
MicroRNAs (miRNAs) play key roles in posttranscriptional gene regulation in nor-
mal biological and pathophysiological processes that underline many human disorders
including neurological diseases [20–27]. MiRNAs are highly sensitive to cellular stimuli
and pathophysiological conditions and are directly involved in the regulation of several
key pathophysiological events following stroke including apoptosis, neuroinflammation,
oxidative stress, brain edema, neurogenesis, and angiogenesis [28–33]. It is thus con-
ceivable that alterations of miRNAs in biofluids might accurately reflect ongoing acute
pathophysiological events. Indeed, the levels of biofluid miRNAs have been associated
with both ischemic and hemorrhage stroke, including subarachnoid hemorrhage [34–37].
A recent metadata analysis supports the notion that different biofluid miRNA fingerprints
are associated with the clinical progression of aSAH and can serve as potential biomarkers
in aSAH management [38]. In this review, we summarize recent research investigating
the association between biofluid miRNAs and aSAH complications, focusing primarily
on potential miRNA indicators of DCV and DCI outcomes. We also discuss the pros and
cons of the different types of specimens, collection times, and analysis methodologies from
the perspective of clinical applications using miRNA biomarkers for the management of
aSAH.
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2. MiRNA in Intracranial Aneurysmal (IA) Tissue and Subarachnoid Hemorrhage
Intracranial aneurysm (IA) is a cerebrovascular disorder in which cerebral artery is
pathologically weakened and ballooned. When ruptured, intracranial aneurysm causes
life-threatening aSAH. It is well documented that miRNAs play fundamental roles in
vascular integrity and vascular function [39–43]. For example, studies have reported that
a deficiency in the miRNA biogenesis machinery protein, DICER, in vascular smooth
muscle cells results in defective blood vessel formation and embryonic lethality [43]. In
addition, miRNAs are aberrantly expressed in the vascular walls following injury [42].
Several studies have confirmed that miRNAs are dysregulated in intracranial aneurysms
(Table 1) [30,44–48]. In 2014, Liu et al. reported that over 150 miRNAs were differentially
expressed in aneurysmal arteries compared to normal arteries [30], demonstrating both
patterns of up- and down-regulation of various miRNAs. However, a previously published
study [45] identified much fewer IA-associated miRNAs (18 miRNAs) with all being
down-regulated. While the reason for the differences between these two studies is not
apparent, it is important to note that the sites of sampling for the control groups between the
studies were significantly different. Specifically, Liu et al. used the extracranial superficial
temporal artery; whereas, Jiang et al. used the intracranial middle meningeal artery. In
addition, a recent study by Supriya et al., employed intercostal artery as the sampling site
for control specimens and identified 70 dysregulated miRNAs in aSAH [47]. Unlike the
above-mentioned studies that analyzed ruptured aneurysmal tissue, Bekelis et al. utilized
unruptured aneurysms to investigate miRNAs as well as protein coding genes in the same
specimen. These authors detected a number of differentially expressed miRNAs and also
significantly altered mRNAs/genes that were reversely correlated with the differential
miRNA expression patterns [44]. Wei and colleagues took a similar approach by analyzing
an existing dataset (GSE54083) originally generated by Nakaoka et al. [49] and identified
12 IA-associated miRNAs that were differentially expressed [48]. However, these authors
did not report whether a reverse correlation exists between the levels of the 12 miRNAs
and the altered gene expression levels.
The majority of identified IA-associated miRNAs include those that are enriched or im-
plicated in endothelial and vascular smooth muscle function (miR-23b, miR-143, miR-145,
miR-9, miR-1, miR-10, miR-17, miR-24-1, and the let-7 family), as well as miRNAs involved
in inflammatory responses and immunity (miR-125b, miR-155, miR-21, and miR-146a).
It is worth mentioning that many of these differentially expressed miRNAs (including
miR-143, miR-145, miR-21, miR-26, miR-29a/b, miR-146a, miR-155, miR-133a, miR-133b,
and let-7 family) are also altered in abdominal aortic aneurysmal tissues [50–53] suggesting
a common mechanism. Interestingly, the levels of several miRNAs (e.g., miR-143, miR-145,
and miR-23b) were found to be consistently down-regulated among the studies described
above [30,45,47,54]. For example, miR-23b was reduced in IA tissues and was reported to
target phosphatase and tensin homolog (PTEN) [55], a key regulator of proliferation, dif-
ferentiation, and cytokine production during pathological vascular remodeling in smooth
muscle cells [56]. MiR-143 and miR-145 play an important role in controlling vascular
smooth muscle phenotype by maintaining or inhibiting differentiation [28,57] and were
found to be significantly down-regulated in IA tissues and plasma [30,44,45,47,54,57]. Con-
sistent with a decrease in miR-143 and miR-145, their predicted target genes, including
those involved in extracellular matrix remodeling, collagen synthesis, and metabolism
(ADAMTS2, COL1A1, COL5A1, and COL5A2), were significantly up-regulated in the
same tissues [44]. In addition, miR-143 and miR-145 were found to target Krüppel-like
factor 5 (KLF5) [54], a transcription factor that plays an essential role in vascular remod-
eling [58] and is strongly induced in activated smooth muscle cells under pathological
conditions [59]. However, rodent studies seem to contradict the observations from the
human studies. Upregulation of miR-143 was observed in cerebral arteries after aSAH in a
rat model [31], and another study found that miR-143 and miR-145 deficiency significantly
reduces atherosclerosis in mice [60]. Further investigations will be required to clarify the
role of these miRNAs in aSAH. Another miRNA regulates endothelial and vascular smooth
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muscle function is miR-9. The expression of miR-9 was found to increase in IA tissues and
negatively regulated MYOCD (Myocardin) [46], a co-activator of serum response factor
(SRF), which play a crucial role in cardiogenesis and differentiation of smooth muscle cell
lineage and is an essential player in controlling vessel contraction [61].
miRNAs are recognized as powerful regulators of central nervous system (CNS)
inflammatory responses [32], including inflammation that occurs following ischemic
stroke and aSAH [29,62–64]. For example, miR-125b was shown to be reduced in IA
tissues [30,47,48], which may target nitric oxide synthase 1 (NOS1) and contribute to
macrophage-mediated vascular smooth muscle cell apoptosis [65]. MiR-155 is a major
inflammatory responsive miRNA that is immune cell-specific and highly inducible [32].
MiR-155 was found to be up-regulated in unruptured IA tissues compared to ruptured
tissues and matrix metalloproteinase-2 was identified as miR-155 target in a report by Yang
et al. [66]. However, miR-155, together with miR-146a, miR-223, and miR-124a, were not
significantly changed according to a previous study [30]. Because the two groups used
different vascular tissues in their studies, the results may not be comparable. In addition,
it is also unclear whether the up-regulation of miR-155 was a result of immune cells that
infiltrated the IA tissue. MiR-21 is a multi-faceted miRNA that participates in the process of
cellular proliferation, migration, and apoptosis in vascular tissues [67]. MiR-21 was found
to be highly up-regulated in unruptured IA tissues [44] and was associated with multiple
downregulated target genes such as poly(A) binding protein interacting protein 2B.
Table 1. Differential miRNA expression in human IA tissues.
Author
Reference/Year Tissue Detection Major Differential Expressed miRNAs
Jiang et al. (2013) [45] 14 IA, 14 MMA Agilent Microarray




Liu et al. (2014) [30] 6 IA, 6 STA Agilent Microarray
let-7 family, miR-17, miR-23b, miR-126,
miR-24-1, miR-222, miR-143, miR-145,
miR-1, miR-10a, miR-125b, miR-26a etc.
Bekelis et al. (2016) [44] 7 UIA, 10 STA Affymetrix Microarray
miR-21, miR-143, miR-145, miR-1246,
miR-6753, miR-6875-3p, miR-4685-3p,
miR3195, miR-6068, miR-193b-5p etc.
Luo et al. (2016) [46] 13 IA, 10 MMA qPCR miR-9
Wei et al. (2018) [48] 8 IA, 10 STA Agilent Microarray miR-125a, miR-125b, miR-145, miR-146a,miR-21, and miR-214
Guo et al. (2018) [55] 32 UIA, 17 PA qPCR miR-23b-3p
Xu et al., 2018 [54] 30 IA, 30 STA qPCR miR-143, miR-145
Yang et al., 2019 [66] 48 IA, 46 UIA qPCR miR-155





IA: intracranial aneurysm; UIA: unruptured IA; MMA: middle meningeal artery; STA: superfacial temporal artery; PA: pulmonary artery;
IcA: intercostal artery.
Taken together, these studies demonstrate a strong involvement of miRNAs in the
pathogenesis of IA and aSAH and provide a wealth of information for studying the
mechanisms associated with these two vascular events. On the other hand, inconsistent
findings are seen across studies, which are most likely due to limitations related to the
heterogeneity of the specimens examined, study design, and small sample sizes.
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3. Alteration of Biofluid miRNAs Associated with aSAH and the Complications
The use of biofluid miRNA biomarkers in aSAH has been explored in a number of
recent studies (Table 2). Encouraging data confirm that dysregulated miRNA expression
is associated with aSAH, DCV, and DCI, and that changes can be observed in biofluids
and circulating blood cells [62,63,68–81]. Importantly, altered miRNA expression levels in
biofluids following aSAH are temporally dynamic and are most noticeable within the first
3 days post-ictus [62,69,71,75,77,81]. This period is critical in aSAH as it directly links the
early, acute brain injuries to DBI, likely through the initiation of a cascade of secondary
events such as oxidative stress, neuroinflammation, and apoptosis [82].
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DCV: delayed cerebral vasospasm; DCI: delayed cerebral ischemia; Ctrl: control; aSAH: aneurysmal subarachnoid hemorrhage; IA:
intracranial aneurysm; UIA: unruptured IA; RIA: ruptured IA; NGS: next-generation sequencing. * The authors gave different account of
what biofluid (plasma, serum) was used. Based on the EDTA-tube being used for the collection, we believed the biofluid used was plasma.
A number of miRNAs have emerged as consistent indicators of aSAH and related
complications (Table 2). For example, based on the results of several observation stud-
ies, many different miRNAs are highly elevated in CSF of aSAH patients compared to
controls [68,69,71,79,81]. In particular, elevated levels of let-7b-5p, miR-19b-3p, miR-125-5p,
miR-221-3p, miR-21-5p, and miR-27a-3p in CSF are all highly predictive of DCV [68,69,79,81].
The alterations of plasma miRNAs in aSAH are less robust, and are substantially
different from that of CSF. Several plasma miRNAs collected at day 3 post ictus, including
let-7a-5p, miR-146a-5p, miR-204-5p, miR-221-3p, miR-23a-3p, and miR-497-5p, showed
strong DCV predictive potential with AUCs ranging from 0.84 to 0.98 [81]. In addition,
elevated miR-3177 was showed to associate with DCV [76]. However, no miRNA was
found to associated with DCV in blood samples collected after day 7 [63], suggesting that
earlier sampling time points may be more optimal. Likewise, differentially expressed
plasma miRNAs collected at day 1 following aneurysm rupture can effectively distinguish
aSAH patients from controls [74,80], but this differential expression pattern is lost when
using the plasma collected at day 3 or later [62,72,81]. These studies strongly suggest that
the timing of sample collection is critical to capture the biomarker signatures associated
with aSAH and associated complications.
Changes in miRNAs following aSAH have been implicated in prognosis in sev-
eral studies. Elevated CSF miR-9-3p and miR-9-5p are associated with poor functional
outcome [69], and serum miR-502-5p and miR-1297 may help predict neurological out-
come [72,77,78]. Unfortunately, to date no miRNA has been identified that significantly
associates with DCI [68,69].
4. Current Limitation of Using miRNAs as Biomarkers for aSAH and
Its Complications
The current management of aSAH and its short and long-term complications relies
solely on imaging and neurological examination [12]. However, this management regime
depends heavily on a “wait and see” approach which can result in therapies that ultimately
miss the optimal treatment window. In addition, imaging and the neurological examination
may not effectively identify pathologic and subtle neurological changes prior to the onset
of a serious complication. These challenges warrant a need for biomarkers that are able to
significantly improve our ability to predict, diagnose, and monitor clinical deterioration.
Although protein and metabolite biomarkers involving neuronal, vascular, angiogenic,
coagulation, and inflammatory response associated with aSAH and its complications have
been analyzed, the sensitivity and specificity are of major concerns for the utility of these
potential biomarkers [85–87]. In particular, several protein markers, such as glial fibrillary
acidic protein, neuro-specific enolase, and S100 calcium binding protein B, a protein in-
volves in BBB dysfunction and brain lesion [88], are also present in stroke and traumatic
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brain injury [89,90]. Compared to protein and metabolite biomarkers, the advantages of us-
ing miRNAs as biomarkers for aSAH and DBI include tissue/cell type, pathophysiological
specificity, and stability in biofluids [91], as well as ease of detection [35,92–94].
The complex and heterogeneity of aSAH pathophysiology is a major challenge in
interpreting the functional involvement of miRNAs as a biomarker for DBI and poor
neurologic outcomes. Unfortunately, the use of miRNA as a biomarker in aSAH is also
currently limited by significant variability in the published literature in the approaches
used, including differences in sample size (between 4 and 129 cases), types of biofluid
used (whole blood, CSF, serum, plasma, exosome etc), collection time points (ranging
from 1 to 14 days to 2 years), different methodologies for miRNA analysis (microarray,
NGS, RT-qPCR), as well as data normalizations. These pre-analytical, analytical, and
post-analytical factors need to be optimized in order to achieve reproducibility during
biomarker discovery and must be established before miRNA biomarkers can be applied in
clinical practice.
4.1. Type of Biofluids
Several types of biofluids including plasma, serum, whole blood, and CSF have been
used to identify valid aSAH biomarkers. Blood (plasma, serum, and whole blood) is the
preferred source for biomarkers in many different diseases and conditions. However,
since blood circulates freely within multiple organ systems, its constituents (proteins,
metabolites, miRNAs etc.) reflect a more global, systemic state, and there can be a high
degree of non-specificity. In addition, many CNS-related molecules are not able to cross
the BBB into the blood stream. These factors make blood as a source of biofluid miRNAs
difficult to interpret. The utility of miRNA analysis in blood may be enhanced by isolating
specific types of exosomes, as they can cross the BBB and may reflect cellular origin and
cell/tissue-specific pathological processes. At this time, the utilization of biofluid exosomes
remains challenging due to a difficult and lengthy isolation procedure, a varied and low
yield, and a lack of specificity for exosome markers [95].
CSF, on the other hand, is highly specific to CNS injuries and conditions, although
more invasive and difficult to sample compared to blood. However, the high frequency of
external ventricular drain placement (>50% of aSAH patients) to treat hydrocephalus and
elevated intracranial pressure [96] allows for access to collection of CSF across multiple
time points. MiRNA alterations in CSF are vastly different from that seen in blood, and the
changes are of a much greater scale. CSF miRNAs are potentially better candidates as aSAH
complication biomarkers and may be more effective in predicting DCV and functional
outcomes [68,69,79,81]. On the other hand, no miRNAs have been identified to consistently
associate with DCI in aSAH. This is largely because of the heterogeneity nature of DCI
and the lack of understanding of the underlying pathophysiological pathways. Future
investigation will need to consider searching additional miRNAs or groups of miRNAs and
other molecules in both CSF and blood to improve the chances of identifying DCI-specific
biomarker(s).
4.2. Specimen Sampling Time
Another caveat with the existing studies is the significant variability of specimen
collection times. Because miRNA responses are associated with a certain biological or
pathological event, the alterations of miRNAs are time-dependent. This is supported by
current studies showing that biofluid miRNAs are temporally dynamic following aSAH
(Table 2). Therefore, it is necessary to determine an optimal sampling time that reflects
the underlying pathology and provides the greatest degree of biomarker differentiation.
Depending on the design and purpose of the study, the sampling times in the published
literature ranges from hours to months to years. For assessing general outcomes and
prognosis, the sampling times may have a wider window during the course of aSAH.
However, when assessing relevant biomarkers for DBI, it is important to sample at early
times (i.e., prior to day 4 following aneurysm ruptured) to ensure that the biomarker is
Int. J. Mol. Sci. 2021, 22, 9492 10 of 16
predictive and may inform clinical decision-making or therapeutic options before non-
reversible complications arise. On the other hand, one should also be cautious about using
samples collected at very early time point, e.g., Day 1 following rupture. The presence of
and changes in miRNAs in these very early samples may be released directly from injured
or dead cells, which may not necessarily be reflective of DBI potential.
4.3. Method of miRNA Detection and Quantification
A significant challenge to quantifying miRNAs is their relatively low level in cell-free
biofluids. Several reports have utilized very time-consuming and costly analytical method-
ologies (such as next-generation sequencing and microarray), which are appropriate for
biomarker discovery but not suitable for clinical practice, especially when dealing with an
aSAH complication and clinical decisions need to be made relatively quickly. Commonly
used miRNA analysis platforms include RNA-Seq (requires higher quantity of RNA/more
expensive/lengthy procedure), microarray (requires higher quantity of RNA/less sensi-
tive/more expensive/lengthy procedure), Nanostring (fast-turn around/able to use poor
quality RNA/less specific/requires special equipment), and qPCR (Table 3). Among these
platforms, qPCR stands out for its sensitivity, specificity, cost-effectiveness, and turn-around
time, all of which are important considerations for future translational applications.
Table 3. Pros and cons of commonly used biofluid miRNA detection platforms.
Detection Methods Pros Cons
RNA-Seq Genome-wide coverage/discovery




Requires higher quantity of RNA/low
sensitivity and specificity/more
expensive/lengthy procedure
nCounter Fast turn-around time/sensitivity/able to useRNA samples of poor quality
No genome-wide coverage or discovery/less
specific/requires special equipment
qPCR Sensitivity/specificity/cost-effectiveness/easyto use/fast turn-around time No genome-wide coverage or discovery
4.4. Data Normalization and Analysis
Different methods of data normalization can profoundly affect the interpretation of
data and the choice of normalization method is essential for miRNA biomarker discovery.
The normalization methods used in the reviewed studies varied drastically. For example,
Meeuwsen et al., [84] selected miR-15b-5p, miR-126-3p, miR-21-5p, miR-30c-5p, and miR-
148b-3p as reference miRNAs. However, several of these miRNAs (such as miR-15b-5p and
miR-21-5p) have been shown in other studies to be altered in aSAH specimens [71,81,83].
Bache et al. [69] specified that they were not able to apply sample mean normalization
method in their dataset due to substantial variations in the mean of each CSF samples.
The group eventually reported the findings based on non-normalized data. Compared to
total RNAs, miRNA data normalization is challenging especially for extracellular biofluid
miRNAs due to the lack of appropriate endogenous controls. Since miRNAs are highly
cell/tissue-specific, it is not possible to identify an appropriate ‘house-keeping’ miRNA.
The use of endogenous miRNAs as normalizers thus is highly empirical, which needs to be
determined in a case-by-case biological context. Several algorithms such as geNorm [97],
NormFinder [98], can be used to assist in identifying stable endogenous miRNAs as
references. Exogenous synthetic oligonucleotides (such as cel-miR-39) are often used as
‘spike-in’ references. These ‘spike-in’ oligonucleotides may serve to monitor the efficacy
of RNA isolation or reverse transcription and can be used to correct qPCR data for the
variability related to these specific processes. However, spike-ins should not be used for
normalization of biological data because they are unable to measure any endogenous
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variability within the specimens. Finally, global mean normalization [99] is useful in
experiments in which there are a large number of miRNA assays. One suggestion for
dealing with normalization challenges is to cross-test or combine different normalization
methods and then validate the differential miRNAs when possible.
5. MiRNA Biomarker Panel for aSAH and Its Complications
The conventional process of biomarker discovery is based on either the understanding
of molecular or biochemical mechanisms of the disease, or by large scale profiling and
screening (aka. -omics). Both approaches have significant challenges in complex hetero-
geneous diseases and pathological conditions, including aSAH. Moreover, the altered
expression of molecule(s) associated with a single pathway may not sufficiently reflect the
underlying complexity of aSAH, and a panel of several molecules/biomarkers that are
involved in multiple pathophysiological processes may be a much more effective strategy.
This strategy is supported by the fact that the levels of multiple miRNAs rather than
that of a single miRNA were significantly altered in IA tissue and aSAH complications
(Tables 1 and 2). We recently piloted a novel approach for developing a miRNA biomarker
panel by creating a disease-focused miRNA panel [100]. We tested this strategy to study
a set of miRNAs as biomarkers for DCV and achieved an 87% prediction accuracy in a
small cohort (Figure 1) [81]. The selected miRNAs on the DCV panel are involved in
multiple pathways such as endothelial and vasculature function, inflammatory/immune
responses, BBB function, apoptosis, angiogenesis, autophagy, and mitochondria function.
We also included potential endogenous normalizers in the panel. We then adapted the
TaqMan qPCR technology to make the analysis fast and cost-effective. We believe such a
biomarker panel can provide an effective tool to improve the sensitivity and specificity of
risk assessment for aSAH and its associated complications.
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Figure 1. A highly predictive miRNA panel for DCV. e i re icti e a el co sists f
iR s that are involved in multiple pathophysiological pathways related to vasculature and brain
injury [81]. The panel also included reference and control miRNAs for data normalization. This panel
was highly predictive of DCV using CSF specimens collected at 3 days following aneurysm ruptured.
6. Perspectives and Concluding Remarks
Biofluid miRNAs hold great potential as biomarkers for aSAH and its complications
although the sensitivity, specifici y, and reproducibility are not yet fully es ablished. Future
s udies aimed at optimizing each stage of biomarker study from sample collection to
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biomarker assays and data analysis will certainly promote the development of miRNAs
as aSAH biomarkers. Furthermore, targeting miRNAs to achieve therapeutic benefits in
aSAH complication management is an attractive perspective and identification of miRNA
biomarkers should provide insights into the mechanistic roles of miRNA in aSAH. In
addition, manipulation of miRNA pathways in aSAH animal models may provide valuable
information on the predictive value and therapeutic potential of miRNAs. Given the
existing evidence and clear potential, it can be argued that the development of strategies
utilizing biofluid miRNAs as aSAH biomarkers is warranted with the ultimate goal of
being applied for the assessment, prediction, diagnosis, and monitoring of aSAH and its
complications.
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